CN1940064A - 溶栓激酶(纳豆激酶)生产方法及其应用 - Google Patents
溶栓激酶(纳豆激酶)生产方法及其应用 Download PDFInfo
- Publication number
- CN1940064A CN1940064A CNA2005100217832A CN200510021783A CN1940064A CN 1940064 A CN1940064 A CN 1940064A CN A2005100217832 A CNA2005100217832 A CN A2005100217832A CN 200510021783 A CN200510021783 A CN 200510021783A CN 1940064 A CN1940064 A CN 1940064A
- Authority
- CN
- China
- Prior art keywords
- thrombolytic
- kinase
- stage
- fermentation
- enzyme
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002537 thrombolytic effect Effects 0.000 title claims abstract description 48
- 239000003146 anticoagulant agent Substances 0.000 title claims abstract description 45
- 108091000080 Phosphotransferase Proteins 0.000 title claims abstract description 36
- 102000020233 phosphotransferase Human genes 0.000 title claims abstract description 36
- 229940086319 nattokinase Drugs 0.000 title claims description 5
- 108010073682 nattokinase Proteins 0.000 title claims description 5
- 238000004519 manufacturing process Methods 0.000 title abstract description 5
- 102000004190 Enzymes Human genes 0.000 claims abstract description 23
- 108090000790 Enzymes Proteins 0.000 claims abstract description 23
- 238000000855 fermentation Methods 0.000 claims abstract description 21
- 230000004151 fermentation Effects 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 13
- 239000004615 ingredient Substances 0.000 claims abstract description 12
- 239000002775 capsule Substances 0.000 claims abstract description 10
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 244000068988 Glycine max Species 0.000 claims abstract description 9
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 9
- 230000008569 process Effects 0.000 claims abstract description 8
- 239000007788 liquid Substances 0.000 claims abstract description 7
- 235000013376 functional food Nutrition 0.000 claims abstract description 6
- 230000002265 prevention Effects 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 4
- 108010074860 Factor Xa Proteins 0.000 claims abstract description 3
- 239000003527 fibrinolytic agent Substances 0.000 claims abstract 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 40
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 20
- 229940088598 enzyme Drugs 0.000 claims description 20
- 235000019152 folic acid Nutrition 0.000 claims description 20
- 239000011724 folic acid Substances 0.000 claims description 20
- 229960000304 folic acid Drugs 0.000 claims description 20
- 230000000694 effects Effects 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 12
- 238000000108 ultra-filtration Methods 0.000 claims description 11
- 238000000926 separation method Methods 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 8
- 239000012528 membrane Substances 0.000 claims description 8
- 238000001471 micro-filtration Methods 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 7
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 6
- 239000000787 lecithin Substances 0.000 claims description 6
- 229940067606 lecithin Drugs 0.000 claims description 6
- 235000010445 lecithin Nutrition 0.000 claims description 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 5
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 229920001542 oligosaccharide Polymers 0.000 claims description 4
- 239000011148 porous material Substances 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 3
- 235000021552 granulated sugar Nutrition 0.000 claims description 3
- -1 maltose oligosaccharide Chemical class 0.000 claims description 3
- 150000002482 oligosaccharides Chemical class 0.000 claims description 3
- 235000000346 sugar Nutrition 0.000 claims description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 2
- 229920000858 Cyclodextrin Polymers 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 229920002774 Maltodextrin Polymers 0.000 claims description 2
- 239000005913 Maltodextrin Substances 0.000 claims description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 2
- 229920000881 Modified starch Polymers 0.000 claims description 2
- 239000004368 Modified starch Substances 0.000 claims description 2
- 239000005862 Whey Substances 0.000 claims description 2
- 102000007544 Whey Proteins Human genes 0.000 claims description 2
- 108010046377 Whey Proteins Proteins 0.000 claims description 2
- 229940041514 candida albicans extract Drugs 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 239000006260 foam Substances 0.000 claims description 2
- 238000011081 inoculation Methods 0.000 claims description 2
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 2
- 229920002521 macromolecule Polymers 0.000 claims description 2
- 229940035034 maltodextrin Drugs 0.000 claims description 2
- 235000019426 modified starch Nutrition 0.000 claims description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 150000008163 sugars Chemical class 0.000 claims description 2
- 238000009423 ventilation Methods 0.000 claims description 2
- 239000012138 yeast extract Substances 0.000 claims description 2
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 abstract description 8
- 108060006633 protein kinase Proteins 0.000 abstract description 8
- 210000004369 blood Anatomy 0.000 abstract description 7
- 239000008280 blood Substances 0.000 abstract description 7
- 150000002632 lipids Chemical class 0.000 abstract description 6
- 206010020772 Hypertension Diseases 0.000 abstract description 5
- 206010003210 Arteriosclerosis Diseases 0.000 abstract description 3
- 229930006000 Sucrose Natural products 0.000 abstract description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract description 3
- 208000007536 Thrombosis Diseases 0.000 abstract description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract description 3
- 235000013373 food additive Nutrition 0.000 abstract description 3
- 239000002778 food additive Substances 0.000 abstract description 3
- 239000008187 granular material Substances 0.000 abstract description 3
- 108010022999 Serine Proteases Proteins 0.000 abstract description 2
- 102000012479 Serine Proteases Human genes 0.000 abstract description 2
- 230000017531 blood circulation Effects 0.000 abstract description 2
- 230000015271 coagulation Effects 0.000 abstract description 2
- 238000005345 coagulation Methods 0.000 abstract description 2
- 238000005516 engineering process Methods 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 229920002472 Starch Polymers 0.000 abstract 1
- 230000002906 microbiologic effect Effects 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- 235000019698 starch Nutrition 0.000 abstract 1
- 239000008107 starch Substances 0.000 abstract 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 10
- 239000000047 product Substances 0.000 description 7
- 244000063299 Bacillus subtilis Species 0.000 description 5
- 235000014469 Bacillus subtilis Nutrition 0.000 description 5
- 208000019622 heart disease Diseases 0.000 description 5
- 229910052742 iron Inorganic materials 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 4
- 239000012510 hollow fiber Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 3
- 239000005515 coenzyme Substances 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- MSTNYGQPCMXVAQ-RYUDHWBXSA-N (6S)-5,6,7,8-tetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-RYUDHWBXSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000005460 tetrahydrofolate Substances 0.000 description 2
- 229960005356 urokinase Drugs 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 108091005658 Basic proteases Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010016880 Folate deficiency Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 235000019764 Soybean Meal Nutrition 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012824 chemical production Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000011868 grain product Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 235000013557 nattō Nutrition 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000017802 other dietary supplement Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 108010073863 saruplase Proteins 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000004455 soybean meal Substances 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000013548 tempeh Nutrition 0.000 description 1
- 238000007395 thrombosis prophylaxis Methods 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000021404 traditional food Nutrition 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明提出发酵法生产高活性溶栓激酶方法和用途,是微生物技术领域技术发明。该发明以农副产品(白砂糖、大豆、淀粉等)为原料,利用枯草杆菌高产溶栓激酶菌株,采用液体深层发酵工艺,复杂系统调控代谢技术,经膜分离技术、冻干等工艺技术生产溶栓激酶。该酶属于丝氨酸蛋白酶,功能用途是溶化血栓、抑制血小板凝固、预防高血压和动脉硬化、调节血脂、保持血流通畅。既可作为医药原料,也可作为功能性食品专用酶,食品添加剂,功能性食品,溶栓药品;可开发成冲剂,片剂、(肠溶)胶囊,口服液等。本发明采用的发酵配料和工艺,提高了溶栓激酶产率,解决了目前溶栓激酶纯化工艺复杂,操作步骤繁杂的问题,该酶经功能性成分科学配伍,可以增强血栓、高血压和高血脂预防和治疗效果。
Description
技术领域
本发明提出发酵法生产溶栓激酶(纳豆激酶)方法及其应用,是微生物技术领域科技发明。主要涉及提高溶栓激酶产率方法,适合工业化生产溶栓激酶膜分离提取方法以及功能性配伍溶栓激酶组合物应用于溶血栓、辅助降血压、辅助调血脂。
技术背景
溶栓激酶是枯草杆菌生长代谢产生的一种易溶于水的胞外碱性蛋白酶,最初由日本学者于1987年从传统食品纳豆中提取得到,命名为纳豆激酶。从1996年起,国内学者也从纳豆类似食品(豆豉、豆酱等豆类发酵食品)中提取得到溶栓激酶,其性质与纳豆激酶基本一致,从豆类发酵食品中分离出微生物经鉴定为枯草芽孢杆菌。经药理实验证明溶栓激酶具有高纤溶活性,不仅具有较强的直接降解纤维蛋白作用,还有激活血管内皮细胞产生组织纤溶酶原激活剂,还能激活尿激酶原产生尿激酶,既可静脉给药,也可口服给药,酶活活性稳定,是一种较为理想的溶栓制剂。
血管栓塞、高血压、血脂水平升高、高血粘、冠心病、中风互相关联常常合并存在,因此,单一成分有一定局限,采用功能性辅助成分配伍,综合防治可以起到协同增效作用。
叶酸(folic acid)又叫叶精,是一种水溶性维生素。叶酸作为辅酶是构成含铁血红蛋白的成分,主要生理功能是预防恶性贫血。叶酸在体内必须转变成具有生物活性的四氢叶酸才能发挥作用。维生素C可将叶酸还原成四氢叶酸。叶酸是蛋白质和核酸合成的必需因子,在细胞分裂和繁殖中起重要作用;使甘氨酸和丝氨酸相互转化,使苯丙氨酸形成酪氨酸,组氨酸形成谷氨酸,使半胱氨酸形成蛋氨酸;参与大脑中长链脂肪酸如DHA的代谢,肌酸和肾上腺素的合成等。膳食中缺乏叶酸将使血中高半胱氨酸水平提高,易引起动脉硬化;膳食中摄入叶酸不足,易诱发结肠癌和乳腺癌。叶酸在正常情况下没有毒性。叶酸易被紫外线破坏,因此,新鲜蔬菜在室温下贮藏2~3天其叶酸量会损失50~70%。食物中50~95%的叶酸在烹调时被破坏。叶酸缺乏症在全世界被公认为一个保健问题。
维生素B12(vitamin B12)是体内多种代谢过程中所必需的辅酶,参与蛋白质、脂肪、糖的代谢。在造血系统中,对红血球的形态和代谢,特别是在DAN合成中作为辅酶,有重要作用。
外源性叶酸、VB12补充剂可预防心脏系统疾病。早有研究证实高半胱氨酸含量偏高的人群更易患中风、心脏病;其心脏系统疾病致死率也会增加。临床试验发现,服用叶酸或VB12补充剂可使体内高半胱氨酸含量分别降低25%、32%。叶酸和VB12具有治疗心脏病的强大潜能。叶酸以及VB12在预防心脏系统疾病方面比大蒜、VE或其它饮食补充物更有效。FDA
曾于1998年发布通知,要求谷类制品(如:面食)中都必须加入叶酸补充剂。据调查,此后美国国民体内的平均高半胱氨酸水平趋于下降。
Vc能增强人体抵抗力,保护微血管,预防坏血病促进伤口愈合。维生素C能增加铁的利用,其生化过程是通过使膳食中三价铁还原为二价铁,促进铁的吸收,再以铁蛋白的形式储存于肝和骨骼中。实践表明,在补充铁的同时补充VC可使铁的吸收率提高22%基本可以达到血红素的正常吸收率。
卵磷脂具有很多的生理功能,在本组方中主要作用是增强老年人的记忆力,延缓脑细胞衰老,预防老年痴呆症。卵磷脂中的不饱和脂肪酸的乳化作用能将体内多余脂肪溶解成极小的颗粒,代谢排除体外,从而达到减肥的目的。防治心脑血管疾病,卵磷脂具有极佳的脂溶乳化性,可以迅速快捷地化解沉积的胆固醇和有害血脂,就像流淌在血管中的清道夫,随时会为您去污除垢,彻底消除心血管疾病的诱因。
目前,发酵法生产溶栓激酶的分离提取工艺多是采用盐析、透析、离子交换、离心、浓缩等才能得到精制溶栓激酶,其提取步骤多,操作复杂,酶活损失大,不利于规模化生产。
发明内容
该发明以农副产品(白砂糖、大豆等)为原料,利用枯草杆菌高产溶栓激酶菌株,采用液体深层发酵工艺,采用复杂系统调控技术优选发酵条件,经膜分离技术、冻干等工艺技术,生产溶栓激酶。该酶属于丝氨酸蛋白酶,功能用途是溶化血栓、抑制血小板凝固,预防高血压和动脉硬化、调节血脂、保持血流通畅。既可作为医药原料,也可作为功能性食品专用酶,食品添加剂,功能性食品;可开发成冲剂,片剂,(肠溶)胶囊,口服液等。
本发明采用的发酵配料和工艺,提高了深层发酵溶栓激酶产率,解决了目前溶栓激酶提取工艺复杂,操作步骤繁杂的问题,提供了一种行之有效、过程短、步骤简单的适合工业化分离提取溶栓激酶的方法。该酶经功能性成分科学配伍,可以增强血栓预防和治疗效果。
实现上述发明内容技术方案:
1、发明涉及的工艺流程
原料→粉碎→配料→灭菌→接种→发酵→膜分离(两级微滤→两级超滤)→冻干,然后按照产品用途包装成成冻干粉原料,或添加功能性成分,制成溶栓激酶组合产品。
2、深层发酵配料和工艺条件
枯草杆菌培养产生溶栓激酶,特征在于:利用碳源有木糖、麦芽糖、葡萄糖和白砂糖,该发明优选白砂糖;利用氮源有大豆(包括豆粕、豆粉、豆饼、大豆蛋白)及其酶解产物、营养素A、玉米提取物;利用无机盐有KH2PO4,K2HPO4,MgSO4·7H2O等;进行深层发酵。
发酵配料
种子培养基:葡萄糖1%,牛肉膏0.3%,蛋白胨1%,KH2PO4 0.2%,K2HPO4 0.4%,pH7.0~pH7.2,0.1MPa、20min。
发酵培养基:蔗糖0.5~5%,黄豆粉0~5%,酵母膏0.1~1%,FeCl30.005~0.01%,泡敌0.2~0.5%,KH2PO4 0.01~0.2%,K2HPO40.2~0.5%,MgSO4·7H2O0.01~0.1%。
发酵工艺条件为发酵罐装量60-80%,通气量为1:0.5~1(V/V),起始pH6.6~pH7.4,灭菌0.1MPa、20~30min,罐压0.03~0.05MPa,种量2~3%,温度32~38℃,搅拌速度280~350rpm,发酵周期42~45小时。
3、分离提取工艺条件和溶栓激酶制备
发酵成熟醪液经预冷;经两级微滤处理得到清亮滤过液;经第一级中空纤维超滤柱,收集渗透液;经第二级中空纤维超滤柱浓缩20余倍,添加辅料(作用是保护酶活,改善品质和加工性能),冷冻干燥,得到微黄色的溶栓激酶粉未。
第一级微滤膜孔孔径为0.2um~0.45um,第二级为0.02um~0.1um,第一级超滤膜孔孔径为300KD~500KD,第二级为5KD~10KD,保持分离系统温度0℃~18℃。
上述溶栓激酶制备涉及辅料包括可溶性糖类、变性淀粉、糊精类(麦芽糊精或环状糊精)、乳清粉,或其中1种或几种。
4、栓激酶应用
枯草杆菌生产的溶栓激酶粉未,可作为医药原料,也可作为功能性食品专用酶,食品添加剂;将溶栓激酶粉未,按口服5000IU~6000IU的剂量加入功能性辅助成分(期待增强溶栓效果),混合得到溶栓激酶组合物,制成冲剂、肠溶胶囊,口服液等,作为心脑血管保健食品和预防或治疗药品。
在上述溶栓激酶应用中,涉及功能性辅助成分包括:叶酸、Vc、卵磷脂、低聚糖(低聚异麦芽或低聚麦芽糖),VB12,或其中1种到几种。其中添加量叶酸1~5毫克/天,Vc100~200毫克/天、卵磷脂0.4~0.5克/天、VB122~6毫克/天,优选低聚异麦芽糖调整容量。
该技术方案优点
经过多批次溶栓激酶深层发酵,微滤澄清、超滤分离和浓缩、冷冻干燥制样,功能性成分科学配伍,分装技术方法试验研究,是行之有效的。具有原料易得,发酵酶活高,工艺流程短,能耗低,操作方便,提取收率高,相对成本低,适合规模化生产等优点。经国家认可的单位进行急毒检测,该产品达到无毒级。经四川大学华西公共卫生学院关于溶栓激酶体外溶栓检测,溶栓效果非常明显。
实例1溶栓激酶的生产
枯草芽胞杆菌斜面菌种活化后,接入摇瓶种子培养基,32~38℃恒温150~250rpm培养24小时,接入发酵培养基,发酵罐发酵42~45小时后出罐。平均酶活达到2100IU,预冷到10℃左右,泵入两级微滤机,收集滤过液,酶活收率90%以上;再经第一级中空纤维超滤去除大分子,第二级中空纤维超滤浓缩达到20余倍,酶活收率80%以上;将溶栓激酶浓缩液添加辅料,冷冻干燥,可以得到酶活20000IU/克以上的固体粉未。
实例2溶栓激酶应用(以胶囊成品为例)
该技术方案生产的溶栓激酶活性(相当于尿激酶)达到20000IU克以上,以日服5000IU,日服2次,每次1粒,可直接装入肠溶胶囊,低聚异麦芽糖调整容量,每粒装量0.25克。
还可将1克溶栓激酶(以20000IU/克计算)冻干粉,组合功能性辅助料叶酸8毫克,Vc400毫克,VB1212毫克,大豆卵磷脂1克,混合均匀,分装肠溶胶囊8粒。
上述产品,作为心脑血管疾病易发人群的保健品,用于预防或辅助治疗血栓类心脑血管疾病。
Claims (7)
1.以辅料、功能性辅助成分组合的溶栓激酶(纳豆激酶),用作医药原料,功能性食品及其添加剂、食品专用酶、溶栓药品;可制成片剂、粉剂、口服液、胶囊等。
2.根据权利要求1所述溶栓激酶采用如下工艺过程生产:原料→粉碎→配料→灭菌→接种→发酵→膜分离(两级微滤→两级超滤)→辅料→冻干(溶栓激酶原料)→功能辅助成分→溶栓激酶组合物。
3.根据权利要求1所述溶栓激酶辅料包括:可溶性糖类、变性淀粉、糊精类(麦芽糊精或环状糊精)、乳清粉,用量按需要的酶活单位任意比添加。
4.根据权利要求1所述溶栓激酶功能性辅助成分及用量分别为:叶酸1~5毫克/天、Vc100~200毫克/天、卵磷脂0.4~0.5克/天、低聚糖(低聚异麦芽糖或低聚麦芽糖)、VB122~6毫克/天。
5.根据权利要求2所述的溶栓激酶发酵配料包括:白砂糖0.5~5%,黄豆粉0~5%,酵母膏0.1~1%,泡敌0.2~0.5%,FeCl3 0.005~0.01%,KH2PO4 0.01~0.2%,K2HPO4 0.2~0.5%,MgSO4·7H2O 0.01~0.1%;发酵工艺条件为发酵罐装量60-80%,通气量为1∶0.5~1(V/V),起始pH6.6~pH7.4,灭菌0.1MPa、20~30min,罐压0.03~0.05MPa,种量2~3%,温度32~38℃,搅拌速度280~350rpm,发酵周期42~45小时。
6.根据权利要求2所述溶栓激酶分离提纯工艺采用以下步骤:
发酵成熟醪液经两级微滤,澄清发酵液经第一级超滤除去大分子物质得到粗酶液;粗酶液经第二级超滤除去小分子物质得到溶栓激酶浓缩液;浓缩酶液添加辅料,经冷冻干燥制成溶栓激酶原料;
提取工艺条件为:第一级微滤膜孔孔径为0.02um~0.45um,第二级为0.02um~0.1um,第一级超滤膜孔孔径为300KD~500KD,第二级为5KD~10KD,保持膜分离系统温度0℃-18℃。
7.一种由权利要求1~6所述的溶栓激酶应用,该酶可与辅料中的一种或几种混合;可与功能性辅助成分中的一种或几种混合,按照所需酶活单位调配,制成以溶栓激酶为主要成分的心脑血管疾病预防或治疗产品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA2005100217832A CN1940064A (zh) | 2005-09-30 | 2005-09-30 | 溶栓激酶(纳豆激酶)生产方法及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA2005100217832A CN1940064A (zh) | 2005-09-30 | 2005-09-30 | 溶栓激酶(纳豆激酶)生产方法及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1940064A true CN1940064A (zh) | 2007-04-04 |
Family
ID=37958589
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2005100217832A Pending CN1940064A (zh) | 2005-09-30 | 2005-09-30 | 溶栓激酶(纳豆激酶)生产方法及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1940064A (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103602651A (zh) * | 2013-11-06 | 2014-02-26 | 北京燕京啤酒股份有限公司 | 一种纳豆激酶生产方法 |
CN106418097A (zh) * | 2016-09-22 | 2017-02-22 | 辽宁天润生物技术有限公司 | 一种可溶性纳豆表层发酵物的制备方法 |
CN106579422A (zh) * | 2016-11-28 | 2017-04-26 | 武汉哈福科技有限公司 | 一种抗血栓的功能性食品 |
CN109402187A (zh) * | 2018-11-15 | 2019-03-01 | 沈阳农业大学 | 天然维生素k2和血栓溶解酶联产方法 |
-
2005
- 2005-09-30 CN CNA2005100217832A patent/CN1940064A/zh active Pending
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103602651A (zh) * | 2013-11-06 | 2014-02-26 | 北京燕京啤酒股份有限公司 | 一种纳豆激酶生产方法 |
CN106418097A (zh) * | 2016-09-22 | 2017-02-22 | 辽宁天润生物技术有限公司 | 一种可溶性纳豆表层发酵物的制备方法 |
CN106579422A (zh) * | 2016-11-28 | 2017-04-26 | 武汉哈福科技有限公司 | 一种抗血栓的功能性食品 |
CN109402187A (zh) * | 2018-11-15 | 2019-03-01 | 沈阳农业大学 | 天然维生素k2和血栓溶解酶联产方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3881494B2 (ja) | 納豆菌培養エキス | |
EP1567022B1 (en) | Sustained improver of muscular fatigue | |
US8618057B2 (en) | Anticoagulant and composition for preventing thrombus containing poly-gamma-glutamic acid | |
CN112999261B (zh) | 一种舒缓动脉硬化的纳豆发酵组合物及其制备方法和应用 | |
KR20010072587A (ko) | 발효유로부터 유래된 골다공증 예방용의 식이성 보충식 | |
Liu et al. | Analysis of main components and prospects of natto | |
TWI590766B (zh) | Thrombotic disease prevention preparation | |
WO2010027014A1 (ja) | S-アデノシル-l-メチオニンの吸収性を高める方法およびs-アデノシル-l-メチオニンの吸収性が高められた組成物 | |
US7138113B2 (en) | Glycoprotein matrix compositions and methods related thereto | |
CN114958948A (zh) | 一种红藻蛋白活性肽及其制备方法和应用 | |
CN1940064A (zh) | 溶栓激酶(纳豆激酶)生产方法及其应用 | |
CN114214366A (zh) | 一种预防和治疗贫血的小肽粉和血红素之肽红复方药物及其制备方法和应用 | |
JP2011132188A (ja) | プラスミノーゲン活性化増強作用を有する乳酸菌及びその組成物 | |
WO2020250980A1 (ja) | 経口剤、癌抑制補助剤及びペット療法食 | |
JP2018145161A (ja) | 血圧上昇抑制組成物およびその製造方法 | |
JP2004115434A (ja) | 糖尿病治療薬 | |
JP3911282B2 (ja) | ビタミンk2の回収方法 | |
CN115530372A (zh) | 一种具有减脂功能的海藻提取物及其制备方法、海藻提取物组合物 | |
US7435565B2 (en) | Bacillus natto culture extract | |
JP4673071B2 (ja) | 鉄吸着性高分子物質及び鉄含有高分子物質ならびにこれらの製造方法 | |
JP2003012538A (ja) | 抗酸化作用剤 | |
CN120037347A (zh) | 一种清理血液垃圾的制备工艺和配方 | |
CN119404998A (zh) | 一种蝮蛇肽复合益生菌固体饮料及制备方法 | |
JP2000080043A (ja) | 水溶性ビタミンk剤 | |
CN117121969A (zh) | 一种纳豆压片糖果及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |